Cost-Effectiveness of Pembrolizumab Versus Carboplatin and Paclitaxel in Patients With Unresectable or Metastatic Melanoma After First-Line Treatment in China

This study aimed to evaluate the cost-effectiveness of pembrolizumab compared with standard-of-care chemotherapy (paclitaxel + carboplatin [PC]) in patients with unresectable or metastatic melanoma after first-line treatment from a Chinese healthcare system perspective. We conducted a partitioned-su...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Value in health regional issues 2022-01, Vol.27, p.99-107
Hauptverfasser:	Tang, Wen-xi, Shao, Rong-jie, Wang, Jingshu, Scherrer, Emilie, Ma, Ai-xia, Aguiar-Ibáñez, Raquel
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized Carboplatin China Cost-Benefit Analysis cost-effectiveness Humans melanoma Melanoma - drug therapy Paclitaxel pembrolizumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!